“Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma: Expansion Cohort Analysis”. 2023. SKIN The Journal of Cutaneous Medicine 7 (2): s179. https://doi.org/10.25251/skin.7.supp.179.